Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:30 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 359 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Zyban Clear all

Conditions: Major Depressive Disorder
Interventions: Cariprazine, Placebo, Antidepressant Therapy (ADT); Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,022 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 83
States / cities: Tucson, Arizona • Little Rock, Arkansas • Cerritos, California + 68 more

Conditions: Major Depressive Disorder
Interventions: Antidepressants through Texas Medication Algorithm (TMA), Brief Interpersonal Psychotherapy (IPT-B); Drug · Behavioral
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 79 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Advanced Chronic Liver Disease, Healthy Participants
Interventions: AZD2389, Midazolam, Caffeine, Bupropion; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Smoking Cessation
Interventions: E-cigarette free access, E-cigarette/NRT/Zyban/Chantix Choice, Outcome Incentive arm, Loss framing incentive arm, Control; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 99 Years
Enrollment: 6,006 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Smoking Cessation
Interventions: Nicotine Patches, Nicotine patches, then bupropion & nicotine patches (Pre-Quit), Nicotine patches, then varenicline (Pre-Quit), Nicotine patches, then nicotine patches (Pre-Quit), Nicotine patches, then bupropion & nicotine patches (Post-Quit), Nicotine patches, then varenicline (Post-Quit), Nicotine patches, then nicotine patches (Post-Quit); Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 606 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Charlotte, Durham, Raleigh, Winston-Salem, North Carolina

Conditions: Smoking Cessation
Interventions: CP-526,555 (varenicline); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 625 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 7
States / cities: Los Angeles, California • Farmington, Connecticut • Minneapolis, Minnesota + 4 more

Conditions: Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI
Interventions: Tranexamic acid (TXA), labetalol, metformin, nifedipine, clindamycin, oxycodone, azithromycin, escitalopram, sertraline, ondansetron, Ciprofloxacin, Doxycycline, Levofloxacin, Methylphenidate, Sumatriptan, Citalopram, Cyclobenzaprine, Furosemide, Gabapentin, Hydrochlorothiazide, Hydroxyurea, Rosuvastatin, Topiramate, Trazodone, Valganciclovir, Venlafaxine, Verapamil, Remdesivir, Anakinra, Tocilizumab, Fluvoxamine, Amoxicillin, Bupropion, Duloxetine, Hydrocodone, Levetiracetam, Paroxetine, Buprenorphine; Drug
Lead sponsor: Duke University; Other
Eligibility: Not listed
Enrollment: 1,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 20
States / cities: La Jolla, California • Loma Linda, California • Chicago, Illinois + 15 more

Conditions: Smokeless Tobacco
Interventions: Bupropion SR; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 225 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Smoking Cessation
Interventions: Usual Care, Smoking Relapse Prevention for Cancer Patients (SRP-CaP); Behavioral
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 441 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Depression, Depressive Disorder
Interventions: Sertraline, Venlafaxine Extended Release; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: New York, New York

Conditions: Nicotine Dependence
Interventions: Varenicline, Bupropion, Nicotine patches, Placebo varenicline, Placebo bupropion, Placebo patch; Drug · Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 2
States / cities: Durham, North Carolina • Raleigh, North Carolina

Conditions: Healthy Volunteer, Cystic Fibrosis
Interventions: PTI-801, Placebo, PTI-808; Drug
Lead sponsor: Proteostasis Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 171 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 33
States / cities: Birmingham, Alabama • Anchorage, Alaska • Stanford, California + 28 more

Conditions: Tardive Dyskinesia, Intellectual Disability, Developmental Disabilities
Interventions: Deutetrabenazine Oral Capsule; Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years to 89 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Lung Cancer
Interventions: placebo, bupropion hydrochloride, nicotine; Other · Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 1,708 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 24
States / cities: Scottsdale, Arizona • Washington D.C., District of Columbia • Peoria, Illinois + 20 more

Conditions: Stimulant Use, Relapse, Cognitive Function, ADHD
Interventions: Contrave 8Mg-90Mg Extended-Release Tablet, Bupropion; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Major Depressive Disorder
Interventions: Not listed
Lead sponsor: Medtronic - MITG; Industry
Eligibility: 21 Years to 75 Years
Enrollment: 375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 10
States / cities: Los Angeles, California • San Diego, California • Torrance, California + 6 more

Conditions: Depression, Major Depressive Disorder, Unipolar Depression
Interventions: Wellbutrin, Placebo; Drug
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Smoking Cessation
Interventions: Bupropion; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Smoking Cessation
Interventions: counseling vs. advice; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years to 80 Years
Enrollment: 689 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Tobacco Use Disorder
Interventions: Bupropion SR, Placebo Oral Tablet; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 64 Years · Female only
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2005
U.S. locations: 1
States / cities: Catonsville, Maryland

Conditions: Cardiovascular Kidney Metabolic Syndrome
Interventions: Intervention, Active Comparator; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 23,280,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Attention Deficit Disorder
Interventions: Extended-release bupropion hydrochloride; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 21
States / cities: Phoenix, Arizona • Chula Vista, California • Lafayette, California + 18 more

Conditions: Amphetamine-Related Disorders
Interventions: Bupropion; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 2
States / cities: Los Angeles, California • Houston, Texas

Conditions: Obesity
Interventions: Naltrexone and Bupropion Combination, Behavioral Weight Loss, Placebo; Drug · Behavioral · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Search by objective public record fields.

Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)

Incorporating Patient Treatment Choice to Improve Treatment Retention in Depressed Hispanics

A Study to Investigate How Multiple Oral Doses of AZD2389 Affect the Pharmacokinetics of Midazolam, Caffeine, and Bupropion in Healthy Participants

Randomized Clinical Trial to Reduce Harm From Tobacco

Evaluation of a Tailored Smoking Cessation Treatment Algorithm Based on Initial Treatment Response and Genotype

A Seven-Week Dose-Ranging Study of CP-526,555 Compared With Placebo and Zyban for Smoking Cessation

Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

Bupropion SR for Treating Smokeless Tobacco Use

Smoking Relapse-Prevention Intervention for Cancer Patients

Improving Retention of Hispanics Receiving Antidepressant Therapy

Mechanistic Evaluations of Pre-Cessation Therapies for Smoking Cessation

Study Assessing the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interactions of PTI-801 in Healthy Volunteers, and Safety, Tolerability, and Pharmacokinetics of PTI-801 in Subjects With Cystic Fibrosis

Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities

Comparison of Nicotine Inhaler and/or Bupropion in Helping People to Stop Smoking and Prevent the Recurrence of Smoking

Relapse Prevention in Stimulant Use Disorder

EEG Biomarkers for Predicting Response to Antidepressant Therapy

The Effects of Wellbutrin (Bupropion) on Residual and Cognitive Symptoms in SSRI-treated Depression

Improving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment

Integrated Smoking Cessation Treatment for Low Income Community Corrections

A Comparison of Bupropion SR and Placebo for Smoking Cessation

Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)

Attention-Deficit Hyperactivity Disorder (ADHD) Study With Adults

Assessment of Potential Interactions Between Methamphetamine and Bupropion - 1

Pharmacological and Behavioral Treatment After Bariatric Surgery